english.prescrire.org > Prescrire International > N°63 - February 2003

n°63

February 2003

Issue Contents
Editorial

Prescrire International: 12 years young!

p.2

Marketing Authorisations

Fondaparinux: no better than LMWH in preventing pulmonary embolism

p.3-5

Verteporfin, new indication in complications of high myopia: no sustained benefit

p.5-8

Complications of high myopia

p.6-7

Telithromycin: a needless addition to the other macrolides

p.8-11

Human protein C: effective replacement therapy for some clotting disorders

p.11-13

Darbepoetin alfa, just a me-too: no advantage in anaemia of chronic renal failure

p.14-16

Treatment of renal anaemia: European and American recommendations

p.15

Ebastine

p.16

Oral itraconazole

p.16

Adverse Effects

Neurological disturbances with valaciclovir

p.17

Chest pain on verteporfin

p.17

Antidepressants and extrapyramidal effects

p.17-18

23rd French pharmacovigilance meeting: outstanding messages

p.17-22

Perinatal exposure to antiretrovirals

p.18

Fluoride osteosis with niflumic acid

p.18

Drug-related hyperprolactinemia

p.18

Severe colchicine-macrolide interactions

p.18-19

Severe hyperkalaemia

p.19

Lithium overdose

p.19

Sideroblastic anaemia and fusidic acid

p.19

Hepatic adverse effects: another example of undernotification

p.19

Tendon abnormalities and hypersensitivity on levofloxacin

p.20

Colonic aphtoid lesions linked to Fleet Phospho-soda°

p.20

Do not combine several NSAIDs

p.20

Report adverse effects demand feedback of information

p.20

Anaphylactic shock with Percutalgine°

p.20-21

Review of coxib adverse effects notified in France

p.21

Muscular adverse effects of statins

p.21

Vasoconstrictor: neurological and cardiovascular adverse effects

p.21

Pregnancy exposed to high-dose buprenorphine

p.21-22

Drug-induced myopia

p.22-23

Pulmonary adverse effects of nitrofurantoin

p.23

Reviews

Treatment of imported uncomplicated malaria: a medical emergency

p.24-25

Fluoroquinolones in ambulatory ENT and respiratory tract infections: rarely appropriate

p.26-27

Treatment of type 2 diabetes

p.28-30

Clinical diagnosis of throat infections: a systemic examination is informative

p.30

Biological diagnosis of group A streptococcal infection

p.30

Outlook

Major therapeutic advances are rare

p.31-32

Research on neglected diseases almost at a standstill

p.32

Value for money?

p.33

Efficacy, safety, and cost of new anticancer drugs (BMJ 2002;325:269-271)

p.33-35

Website of the French Agency for Health Product Safety (AFSSAPS): progress at a snail's pace

p.36-37

Prescrire's criteria for assessing drugs agency websites

p.37

Forum

The PROGRESS trial: was it unfairly reported by Prescrire?

p.38-39

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe